Maze Therapeutics initiated with an Overweight at Wells Fargo

Wells Fargo initiated coverage of Maze Therapeutics (MAZE) with an Overweight rating and $55 price target The firm cites the company’s “underappreciated potential” in broad APOL1-mediated kidney disease and a backdrop of rising interest in rare kidney assets for the buy rating. Maze’s multiple internal and external catalysts in 2026 could de-risk its $3B peak sales opportunity in the U.S., the analyst tells investors in a research note.